Theracryf Plc Announces Director Shareholding Change
Why we think this is neutral
This RNS announcement is a routine director shareholding notification, which does not contain any significant business updates or financial information. As a result, the overall sentiment is neutral.
Key Points
- Director Simon Gibeon has acquired 71,400,000 shares in Theracryf Plc
- The shares represent 3.3527% of the company's total voting rights
Summary
The healthcare company has announced a change in director shareholding.
Theracryf Plc, a clinical stage therapeutics company, has announced a change in director shareholding. According to the RNS, director Simon Gibeon has acquired 71,400,000 shares, representing 3.3527% of the company's total voting rights.
DIRECTOR DEALINGS